IGF2BP2靶基因在肿瘤糖代谢及放疗抵抗中的研究进展  

Research progress of IGF2BP2 target genes in tumor glucose metabolism and radiotherapy resistance

作　　者：张奇 刘小军 王瑞麟 王国印 田玉婷 李淑萍 ZHANG Qi;LIU Xiaojun;WANG Ruilin;WANG Guoyin;TIAN Yuting;LI Shuping(First Clinical Medical School,Gansu University of Chinese Medicine,Lanzhou 730000,China;Department of Radiotherapy,Gansu Provincial Hospital,Lanzhou 730099,China)

机构地区：[1]甘肃中医药大学第一临床医学院,甘肃兰州730000 [2]甘肃省人民医院放疗科,甘肃兰州730099

出　　处：《空军军医大学学报》2024年第11期1319-1323,共5页Journal of Air Force Medical University

基　　金：甘肃省自然科学基金(21JR7RA618,21JR7RA623);甘肃省人民医院科研基金(21GSSYA-2)。

摘　　要：胰岛素样生长因子2 mRNA结合蛋白2(IGF2BP2)通过靶向识别mRNA上的N6甲基腺苷(m6A)参与增强一些恶性肿瘤的进展,并与患者耐药、较差的预后相关。IGF2BP2的下游靶基因在调节细胞的葡萄糖代谢、介导放疗抵抗等方面扮演着至关重要的角色。本文就IGF2BP2下游靶基因在肿瘤放疗敏感性中的研究进展作一综述,在揭示放疗抵抗新机制的同时,以期为今后临床及科研的靶向研究提供新思路。Insulin-like growth factor 2 mRNA-binding protein 2(IGF2BP2)is involved in enhancing the progression of some malignant tumors by targeting recognition of N6-methyladenosine(m6A)on mRNA and is associated with drug resistance and poor prognosis in patients.The downstream target genes of IGF2BP2 play a crucial role in regulating glucose metabolism and mediating radiotherapy resistance.In this paper,the research progress of IGF2BP2 downstream target genes in tumor radiotherapy sensitivity is reviewed,in order to reveal the new mechanism of radiotherapy resistance,and provide new ideas for future clinical and scientific targeting research.

关 键 词：IGF2BP2 AKT MYC HIF 糖酵解 放疗抵抗 

分 类 号：R730.5[医药卫生—肿瘤]